Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Regeneron Pharmaceuticals, Inc. v. Amgen Inc.
Case Number:
1:22-cv-00697
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 31, 2022
Regeneron Rips Amgen's 'Bundling Scheme' Amid IP Feud
Regeneron Pharmaceuticals Inc. has launched a new antitrust lawsuit accusing Amgen of an illegal "bundling scheme" aimed at destroying the market for Regeneron's cholesterol medication Praluent and boosting sales of its main rival product, Amgen's Repatha.
- ← Previous
- 1
- 2
- Next →